iCoat Medical today publishes its Annual Report for the financial year 2022. The Annual Report is attached to this press release and available on the company’s website www.icoatmedical.com The Annual Report is only available in Swedish.
For additional information, please contact:
Peder Waern, CEO – iCoat Medical AB
Mattias Springare, CFO – iCoat Medical AB
iCoat Medical is a clinical stage, immunotherapy company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world’s leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform. iCoat Medical’s lead candidate TUM012 is developed to improve the outcome of organ transplantations. The company’s unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund and Malmö, and is headquartered in Stockholm.